Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Jill Steidl"'
Autor:
Adam P. Hill, Zhen Song, Haibo Ni, Norman Stockbridge, David G. Strauss, Jamie I. Vandenberg, Todd Wisialowski, Mikiko Nakamura, Takashi Yoshinaga, Godfrey L. Smith, Jill Steidl‐Nichols, Mark Holbrook, Stefano Severi, Pierre Morissette, Derek J. Leishman, Colleen E. Clancy, Gary R. Mirams, Andrea Greiter-Wilke, Andrew G. Edwards, Xiaomei Han, Zhihua Li, Flora Musuamba Tshinanu, Stefano Morotti, Stephane Nave, Aaron Fullerton, Bradley J. Ridder, Zhilin Qu, Michelangelo Paci, Alfonso Bueno-Orovio, Janell E. Chen, Thomas Singer, Peter R. Kowey, Liudmila Polonchuk, Eric A. Sobie, Blanca Rodriguez, Randall L. Rasmusson, Elisa Passini, Eleonora Grandi, Ken Wang, Michael Liu, Bruce P. Damiano, Xin Zhou
Publikováno v:
Clinical pharmacology and therapeutics, vol 107, iss 1
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics
This white paper presents principles for validating proarrhythmia risk prediction models for regulatory use as discussed at the In Silico Breakout Session of a Cardiac Safety Research Consortium/Health and Environmental Sciences Institute/US Food and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc2ff4e1c2fbbbeb607662c3df93ed0e
https://doi.org/10.1002/cpt.1647
https://doi.org/10.1002/cpt.1647
Autor:
Gregory S. Friedrichs, David G. Strauss, Ariane Menard, Jill Steidl-Nichols, Jean-Michel Guillon, Nicolas Gendron-Parra, Simon Authier, Jean-Pierre Valentin, Ray W. Chui, Jennifer B. Pierson, Michael K. Pugsley, Eric I. Rossman, Todd Wisialowski, Matthew M. Abernathy, Emmanuel Boulay, John Koerner, Andrea Greiter-Wilke, Eric Troncy
Publikováno v:
International Journal of Toxicology. 38:23-32
Introduction: Based on the ICH S7B and E14 guidance documents, QT interval (QTc) is used as the primary in vivo biomarker to assess the risk of drug-induced torsades de pointes (TdP). Clinical and nonclinical data suggest that drugs that prolong the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef70e5850a2a9fe87809255931a38c98
https://doi.org/10.1177/1091581818813601
https://doi.org/10.1177/1091581818813601
Autor:
Donglin Guo, Bernard Fermini, David S. Ramirez, Stephen Jenkinson, Asser Bassyouni, Jason Cordes, Todd Wisialowski, Sunny Z. Sun, David M. Potter, Jill Steidl-Nichols
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 89:9-18
Introduction Cardiac sodium channel antagonists have historically been used to treat cardiac arrhythmias by preventing the reentry of the electrical impulse that could occur following myocardial damage. However, clinical studies have highlighted a si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8af8646dabdbc80e028ae938b088d883
https://doi.org/10.1016/j.vascn.2017.10.002
https://doi.org/10.1016/j.vascn.2017.10.002
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology. 169(1)
Cardiovascular (CV) safety-related attrition is an important contributor to the loss of promising drug candidates during development. CV safety pharmacology studies are conducted to identify these safety effects. Understanding translation of CV endpo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a49718ac1e832626ebb1ceb3e771ae
https://pubmed.ncbi.nlm.nih.gov/30726989
https://pubmed.ncbi.nlm.nih.gov/30726989
Autor:
Sarah H. Lopes, David Blackwell, Makeida Stubbs, Peter Harris, Robert Barnes, Sandy Summers, William J. Reagan, Jill Steidl-Nichols
Publikováno v:
Toxicologic Pathology. 45:335-343
Limited information has been published on the use of cardiac troponin I (cTnI) as a biomarker of cardiac injury in monkeys. The purpose of these studies was to characterize the cTnI response seen in cynomolgus macaques during routine dosing and blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a229e4a48e552179cb6266acf289a82f
https://doi.org/10.1177/0192623316663865
https://doi.org/10.1177/0192623316663865
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 73:49-55
Introduction Drug induced orthostatic hypotension (OH) is an important clinical concern and can be an unexpected hurdle during drug development. OH is defined as an abnormal decrease in blood pressure (BP) triggered by a rapid postural change. The sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2343d05f010c3cf52be02b5f6b64777d
https://doi.org/10.1016/j.vascn.2015.03.003
https://doi.org/10.1016/j.vascn.2015.03.003
Autor:
Thomas Cummings, Paul Butler, David L. Shelton, Mark T. Butt, Rosalinda Arends, Jill Steidl-Nichols, Stephen Foote, Siddhartha Bhatt, Susan Hurst, David Potter, Patrice Belanger, Carlin Okerberg, Mark Zorbas, Mark G. Evans
Publikováno v:
Toxicological Sciences
Tanezumab, a humanized monoclonal antibody against nerve growth factor is in development for treatment of chronic pain. Three nonclinical studies assessed effects of clinically relevant and supratherapeutic doses of tanezumab on the sympathetic nervo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57a193ec349903e4d00c1e9f2e69311d
https://pubmed.ncbi.nlm.nih.gov/28525647
https://pubmed.ncbi.nlm.nih.gov/28525647
Autor:
Declan Flynn, Michelle Hemkens, Todd Wisialowski, Siddhartha Bhatt, Jill Steidl-Nichols, Dingzhou Li
Publikováno v:
Journal of pharmacological and toxicological methods. 81
Cardiovascular (CV) toxicity and related attrition are a major challenge for novel therapeutic entities and identifying CV liability early is critical for effective derisking. CV safety pharmacology studies in rats are a valuable tool for early inves
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::892c8806411c14f3c86bcefb7c7b9f6f
https://pubmed.ncbi.nlm.nih.gov/27071954
https://pubmed.ncbi.nlm.nih.gov/27071954
Autor:
E. Blasi, A. John-Baptiste, Aileen D. McHarg, S. Patyna, Jonathan R. Heyen, Jill Steidl-Nichols, Michelle Hemkens, D. Ramirez
Publikováno v:
Cardiovascular Therapeutics. 30:287-294
SUMMARY Background: Sunitinib, a multi-tyrosine kinase inhibitor has demonstrated clinical activity in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumor. It has been associated with manageable hypertension
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbfba77b636336b1c1390b89e1478111
https://doi.org/10.1111/j.1755-5922.2011.00278.x
https://doi.org/10.1111/j.1755-5922.2011.00278.x
Autor:
Rob Wallis, Derek J. Leishman, Aileen D. McHarg, Ruei-Che Liu, Jill Steidl-Nichols, Joanne Leaney, Gilles Hanton
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 57:9-22
Introduction Prediction of the propensity of a compound to induce Torsades de Pointes continues to be a formidable challenge to the pharmaceutical industry. Development of an in vitro model for assessment of proarrhythmic potential offers the advanta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d49f7ab57061a251ff23290b71a824ed
https://doi.org/10.1016/j.vascn.2007.06.003
https://doi.org/10.1016/j.vascn.2007.06.003